Partner of Biopharma & Healthcare sector• Achieved the $10mil Bio Project Fund for microbiome, antibody discovery platform, biomarker based anti-cancer drug and automated flow cytometry companies- Established portfolio strategy and sourced attractive deals for equity and secondary investment, prepared funding proposal for potential limited partners and accomplished the 1st Biotech Fund

Investment professional in Biopharma & Healthcare sector• Invested in 14 biopharma and healthcare companies (total $80mil, seed stage to Pre-IPO) and exited 6 companies • Accomplished two ‘Global Healthcare PEF’ for a Microbiology IVD platform company and an Immuno-oncology new drug developer, each $7mil and $22mil.• Led overseas investments and invested in Chinese and US biotech companies totalling $35mil. The Chinese biotech listed on NASDAQ in Jan. 2020 and the US biotech is preparing for KOSDAQ listing in 2021. • Actively engaged in value-added activities and strategic guide for invested companies. - As a company builder, shared the competitive advantage, cleared inefficient pipeline and focused on the core product, leading to the strategic collaboration with big pharma- Introduced the U.K based healthcare advisory firm for global licensing of NASH pipeline, resulting in making a contract with the firm after positive review.- Connected two invested companies, leading to business partnership for IP protection and revenue increase through new formulation and production.

• Led the Disease Management team as a team leader covering key functional units - service planning, clinical studies, KFDA approval of diabetes mgmt. solution for patients and physicians. The solution received final approval from KFDA, CE and ISO 13485.• Collaborated with Chinese premium clinic to launch Chinese ver. Diabetes solution in premium clinic in Shenzhen and hospitals in Wuxi.

• Proposed ‘business restructuring’ plan in the third year for slimming the organization, reducing unnecessary costs while maintaining core business. After execution, company reduced fixed cost by 30%, making business unit more flexible. • Managed a $15mil R&D fund for digital healthcare research and established annual business and budget planning and set-up operational processes from the beginning

• Analyzed the future bio-healthcare industry, selected CJ group’s promising red-bio business opportunities and proposed implementation of roadmaps for execution of corporate strategy.• Actively participated M&A strategy for local pharmaceutical and medical device companies• Discovered potential collaborative partners and made an agreement with India pharma for bio-better product through detailed due diligence for execution of corporate strategy• Marketing and Sales collaboration with multinational pharma companies (MSD, Pfizer, Sanofi) • Production Alliance with KBCC (Korean Biotech Commercialization Center)

• Assisted in planning the ‘GSK Korea’s Long-Term Strategy’ preparing commercial strategy for new vaccine products as well as existing ones.

• Prepared long-term business plan and R&D reformation with Booz & Co. global consulting firm• Made a co-promotion agreement with a French pharma company for anti-hypertensive drug.• Planned for R&D department integration and transfer project in terms of financial and operational aspects.